Research & Development

Innovac raises funding for lead programmes development

Innovac Therapeutics has raised $18m in Series Pre-A financing for funding the development of its lead programmes and manufacturing capabilities.

Allucent to expedite Covid-19 booster vaccines development

Allucent has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to expedite clinical research and development of next-generation booster vaccines for Covid-19.

Daiichi Sankyo to close Japanese research and development subsidiary

Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.

Solu Therapeutics raises funds to develop CyTaC platform and drug candidates

Precision-medicine company Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.

Viatris, Kindeva launch Breyna to treat asthma and COPD patients

Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.

Charles River Laboratories, Curigin partner on gene therapy

Charles River Laboratories International has teamed up with Korean biotechnology company Curigin for producing oncolytic ribonucleic acid interference (RNAi) gene therapy.

EdgeCap Partners buys majority stake in Comac Medical

Private equity and growth capital firm EdgeCap Partners has acquired a majority stake in Bulgarian clinical research solutions organisation (CRO) Comac Medical.

SGS picks 60% stake in Nutrasource

Swiss company SGS has purchased a majority stake in Nutrasource Pharmaceutical and Nutraceutical Services as well as its subsidiaries (Nutrasource).

Sandoz, Just – Evotec Biologics tie up to develop multiple biosimilars

Sandoz and Evotec’s Seattle-based subsidiary, Just - Evotec Biologics have reached a multi-year, long-term tech alliance to develop and manufacture multiple biosimilars.